Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Predictive Value of 16α-[18F]-Fluoro-17β-Estradiol PET as a Biomarker of Progestin Therapy Resistance in Patients With Atypical Endometrial Hyperplasia and Low-Grade Endometrial Cancer

Yamada, Shizuka, MD*; Tsuyoshi, Hideaki, MD*; Tsujikawa, Tetsuya, MD; Okazawa, Hidehiko, MD; Yoshida, Yoshio, MD*

doi: 10.1097/RLU.0000000000002612
Interesting Images
Buy

For early-stage endometrial cancer patients who wish to preserve fertility, progestin treatment is effective. However, repeated endometrial curettage to evaluate treatment response may cause infertility. The clinical courses of 3 patients who were treated with fertility-sparing progestin treatment and underwent serial 18F-FES PET before and after treatment are presented. The SUVmean decreased greatly in patients with pathologically complete response (44.2%, 46.2%), whereas there was only a small change (22.5%) in the patient with pathologically stable disease who finally underwent hysterectomy. 18F-FES PET can be a noninvasive method to evaluate response to fertility-sparing progestin treatment.

From the *Department of Obstetrics and Gynecology, Faculty of Medical Sciences, and

Biomedical Imaging Research Center, University of Fukui, Fukui, Japan.

Received for publication November 14, 2018; revision accepted March 25, 2019.

Conflicts of interest and sources of funding: This study was partly supported by grants-in-aid for scientific research from the Japan Society for the Promotion of Science (nos. 15H04981, 16K20181, and 16K10345). None declared to all authors.

Correspondence to: Hideaki Tsuyoshi, MD, Department of Obstetrics and Gynecology, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan. E-mail: go242h@yahoo.co.jp.

Online date: May 17, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.